Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 24, 2017
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
[ Fri, Mar 24th 2017
] - WOPRAI
Liana Moussatos Reiterated (ASND) at Buy with Increased Target to $34 on, Mar 24th, 2017
Liana Moussatos of Wedbush, Reiterated "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $31 to $34 on, Mar 24th, 2017.
Liana has made no other calls on ASND in the last 4 months.
There are 2 other peers that have a rating on ASND. Out of the 2 peers that are also analyzing ASND, 1 agrees with Liana's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Joseph Schwartz of "Leerink Swann" Downgraded from Buy to Hold and Increased Target to $30 on, Thursday, March 9th, 2017
This is the rating of the analyst that currently disagrees with Liana
- Alethia Young of "Credit Suisse" Initiated at Buy and Held Target at $28 on, Thursday, February 9th, 2017
